Today, on 18 April 2024, Magle Chemoswed Holding AB (publ) has published its interim report for Q1, 2024.
Q1 2024 KEY INDICATORS
- Net sales amounted to 38.2 MSEK (38.7)
- EBITDA equalled 7.0 MSEK (7.5)
- Operating profit (EBIT) is 4.1 MSEK (4.3)
- Profit after tax amounted to 2.9 MSEK (2.9)
- Earnings per share SEK 0,3 (0,3) per share
Justin Pierce, Magle Group's CEO commented on the results, stating, "We are pleased to report another strong quarter for Magle Group, which reflects our unwavering focus on delivering innovative solutions and superior value to our partners and patients. Despite a challenging macroeconomic environment, we have managed to maintain a solid profit margin and steady revenues. Our results are a testament to the hard work and dedication of our team, and our ability to adapt and thrive in a rapidly evolving marketplace. Looking ahead, we remain committed to investing in our core business areas, exploring new opportunities for growth, and continuing to enhance shareholder value."
Contacts
Justin Pierce, CEO, phone +46 (0)70 593 58 21, justin.pierce@maglechemoswed.com
About Us
The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes two operational areas. Magle Chemoswed - a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept - an established sales and marketing company for development and direct sales of the Groups medical technology products. Learn more on www.maglechemoswed.com and https://maglegroup.com/ and www.maglepharmacept.com
Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.
